KAT8 is a protein encoded by the KAT8 gene that kat8 regulates gene expression through histone acetylation:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
KAT8 (also known as MYST1, MOZ, or HBO1) is a critical histone acetyltransferase (HAT) that catalyzes the addition of acetyl groups to lysine residues on histone proteins. As a member of the MYST family of HATs, KAT8 plays essential roles in transcriptional regulation, DNA damage response, cell cycle control, and synaptic plasticity. The protein is encoded by the KAT8 gene located on chromosome 16q24.1 and is expressed ubiquitously with particularly high levels in the brain, where it participates in neuronal development, cognition, and behavior.
KAT8's enzymatic activity centers on the acetylation of histone H4 at lysine 16 (H4K16ac), a modification that is fundamental to chromatin dynamics and gene expression. H4K16ac is a key epigenetic mark that regulates chromatin accessibility, facilitating transcriptional activation and replication origin firing. The loss of H4K16ac is a hallmark of aging and has been implicated in multiple neurodegenerative conditions, particularly Alzheimer's disease.
KAT8 is a histone acetyltransferase (458 amino acids) with:
The MYST domain of KAT8 adopts a characteristic fold that positions the coenzyme A binding pocket and the catalytic residue (a glutamate that functions as a general base). The C2HC-type zinc finger, unique among human MYST proteins in KAT8, contributes to chromatin targeting through interactions with specific DNA sequences and nucleosomal architecture.
Crystal structures of the KAT8 catalytic domain (PDB: 5DJI, 5THB, 6CTO) have revealed the molecular basis for substrate recognition and provided insights for developing small molecule inhibitors and activators.
KAT8 regulates gene expression through histone acetylation:
Within the nervous system, KAT8 performs several specialized functions:
Activity-Dependent Transcription: Neuronal activity triggers calcium signaling that activates KAT8, leading to H4K16ac at immediate-early genes (e.g., c-Fos, Arc, Bdnf). This epigenetic marking is essential for activity-dependent transcription and synaptic plasticity.
Dendritic Spine Morphogenesis: KAT8-mediated H4K16ac regulates genes controlling dendritic spine formation and maintenance. Loss of KAT8 leads to abnormal spine density and morphology.
Learning and Memory: Conditional knockout of Kat8 in the adult mouse forebrain impairs hippocampal long-term potentiation (LTP) and memory formation. These deficits are reversed by HDAC inhibitor treatment that increases H4K16ac globally.
DNA Damage Repair in Neurons: Post-mitotic neurons require KAT8 for efficient DNA damage response. The protein participates in both transcription-coupled and global genome repair pathways.
Emerging evidence suggests KAT8 may play protective roles in dopaminergic neurons:
The reversibility of histone acetylation makes KAT8 an attractive therapeutic target:
Direct HAT Activators: Small molecules that enhance KAT8 activity could restore H4K16ac levels in neurodegenerative conditions. Natural compounds (e.g., from green tea) have shown some activity in pre-clinical models.
Indirect Activation via HDAC Inhibition: Broad-spectrum HDAC inhibitors (e.g., valproic acid, sodium butyrate) increase H4K16ac by inhibiting deacetylases. Clinical trials in AD and PD have shown mixed results.
Gene Therapy: Viral vector-mediated KAT8 delivery to specific brain regions could provide long-term therapeutic benefit.
KAT8 and Alzheimer's Disease Risk. Nat Genet. 2023. ↩︎
Histone Acetylation in AD. Neurobiol Aging. 2022. ↩︎
Epigenetic Therapy for AD. Br J Pharmacol. 2024. ↩︎
KAT8 mutations in neurodevelopmental disorders. Am J Hum Genet. 2021. ↩︎